Authors’ Response to Peer Reviews of “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis”

Similar Items

• Authors’ Response to Peer Reviews of “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis”
  by: Tigran Makunts, et al.
  Published: (2024-05-01)
• Depression Events Associated with Proton-Pump Inhibitors in Postmarketing Drug Surveillance Data
  by: Tigran Makunts, et al.
  Published: (2023-08-01)
• Hepatic injury and hepatic failure adverse events in 3,4-methylenedioxymethamphetamine users reported to the FDA Adverse Event Reporting System
  by: Tigran Makunts, et al.
  Published: (2024-06-01)
• Peer Review for “Thyroid Hyperplasia and Neoplasm Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists in the Food and Drug Administration Adverse Event Reporting System: Retrospective Analysis”
  Published: (2024-05-01)
• Anti-TNF-α therapy induced psoriasis in rheumatoid arthritis patients according to FDA postmarketing surveillance data
  by: Haroutyun Joulfayan, et al.
  Published: (2023-06-01)